Skye Bioscience (SKYE) Appoints Paul Grayson as Chairman
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/2/2026
- Wall St futures rise as AI stocks catch their breath; midterms in focus
- Marvell agrees $115 billion all-stock deal to buy Lumentum
- Oil drops over 4% on hopes of progress in talks on ending US-Iran war
- Why has the market become so unforgiving of AI earnings?
- EchoStar rises on report SpaceX in talks to buy Boost Mobile or tap its network
- Marvell agrees to acquire Lumentum in all-stock deal valued at $115B
- Cipher Digital posts Q3 revenue of $27M, logs first HPC lease income
- Binance sees spike in withdrawals as exchange returns online after $6.3 billion heist
- Iran, Qatari mediators hold third day of talks to end US-Iran war
- Marvell to buy Lumentum in $115 billion deal in AI data-center bet
- After-Hours Movers: AMZN, TWLO, INTC, SNDK, RDDT, RBLX, PINS, RIVN, SBUX, ILMN
- After-Hours Movers: GOOGL, MSFT, NOW, KLAC. CMG, CVNA, TDOC
- After-Hours Movers: STX, ENPH, HOOD, V, CSGP, BOOM, CAKE, PPG, OI, TER
- After-Hours Movers: CLS, AVGO, CDNS, AMKR, WHR
- After-Hours Movers: WDC, BE, DECK, FIX, RNG
Skye Bioscience Names Independent Director Paul Grayson as Chairman of the Board
October 29, 2024 7:00 AM EDTSAN DIEGO, Oct. 29, 2024 (GLOBE NEWSWIRE) -- Skye Bioscience, Inc. (Nasdaq: SKYE) (Skye), a clinical-stage biopharmaceutical company focused on unlocking new therapeutic pathways for metabolic health, today announced the Board has appointed independent director Paul Grayson as Skyes new Chairman of the Board, effective October 25, 2024. Mr. Grayson currently serves as a member of Skyes Audit, Compensation and Nominating and Corporate Governance Committees. Punit Dhillon, Skyes Chief Executive Officer, will continue to serve as a member of the Board.
Punit Dhillon, Skyes Chief Executive Officer and former Chairman of the... More



